Transplantation Compatibility Testing in Clinical Immunology

Immunological Principles of Allorecognition and the HLA Complex

• Foundations of Transplantation Histocompatibility:

  • Successful solid organ transplantation and hematopoietic stem cell transplantation (HSCT) necessitate circumventing alloreactive recipient immune responses against foreign donor tissues.

  • Histocompatibility testing systematically characterizes donor and recipient immunological barriers to prevent graft rejection and optimize long-term graft survival.

  • Rejection is predominantly driven by genetic polymorphisms within the Major Histocompatibility Complex (MHC), termed the Human Leukocyte Antigen (HLA) system in humans, located on the short arm of chromosome 6 at locus $6\text{p}21.3$.

• Genetic Organization of Chromosome $6\text{p}21.3$:

  • The HLA genetic region represents the most polymorphic locus in the entire human genome.

  • The genetic architecture spans from the centromere toward the telomere in three distinct classes:

  • Class II Region (Centromeric): Encodes HLA-DP, HLA-DQ, and HLA-DR.

  • Class III Region (Central): Encodes non-HLA immune proteins, including complement components ($C2$, $C4$, Factor B) and cytokines such as Tumor Necrosis Factor (TNF).

  • Class I Region (Telomeric): Encodes HLA-B, HLA-C, and HLA-A.

• HLA Class I Molecular Structure and Expression:

  • Includes classical loci HLA-A, HLA-B, and HLA-C.

  • Cellular Distribution: Expressed constitutively on virtually all nucleated cells and blood platelets.

  • Structure: Heterodimer composed of a polymorphic heavy alpha ($\alpha$) glycoprotein chain non-covalently coupled to an invariant beta-2-microglobulin ($\beta_2\text{m}$) light chain.

  • Immunological Function: Displays endogenous intracellular peptides to $CD8^+$ cytotoxic T lymphocytes.

• HLA Class II Molecular Structure and Expression:

  • Includes classical loci HLA-DR, HLA-DQ, and HLA-DP.

  • Cellular Distribution: Expressed constitutively on professional antigen-presenting cells (APCs), including dendritic cells, B lymphocytes, and macrophages; expression is inducible on vascular endothelial cells under inflammatory signaling (e.g., exposure to interferon-gamma).

  • Structure: Heterodimer formed by non-covalently associated polymorphic alpha ($\alpha$) and beta ($\beta$) transmembrane glycoprotein chains.

  • Immunological Function: Displays exogenous internalized peptides to $CD4^+$ helper T lymphocytes.

• Pathways of Allorecognition:

  • Direct Allorecognition:

  • Recipient circulating T lymphocytes directly encounter and bind intact, allogeneic HLA molecules presented on donor passenger leukocytes (such as donor-derived dendritic cells residing within the graft).

  • An estimated $1\text{--}10\%$ of circulating recipient T cells possess intrinsic TCR cross-reactivity with foreign intact MHC molecules.

  • Serves as the primary immunological driver of vigorous, early acute cellular rejection (ACR).

  • Indirect Allorecognition:

  • Recipient APCs take up, process, and present shed allogeneic donor HLA peptides in the groove of self-HLA Class II molecules to recipient $CD4^+$ helper T cells.

  • Follows the conventional physiological model of foreign antigen presentation.

  • Primarily mediates chronic allograft rejection, vasculopathy, and the emergence of de novo donor-specific antibodies (dnDSA).

  • Semi-Direct Allorecognition:

  • Recipient APCs acquire intact, whole donor MHC molecules directly from donor cells via intercellular membrane transfer (trogocytosis) or extracellular vesicle/exosome fusion.

  • The acquired intact donor MHC molecules are integrated into the recipient APC membrane and presented directly to recipient T cells without requiring intracellular lysosomal peptide processing.

ABO and Vascular Endothelial Histocompatibility

• The ABO Immunological Barrier:

  • Carbohydrate A and B antigens are expressed abundantly on the luminal surface of vascular endothelial cells, representing the primary immunological hurdle in solid organ transplantation.

  • Pre-existing naturally occurring recipient isohemagglutinins ($IgM$ and complement-activating $IgG$ directed against non-self ABO blood group antigens) mediate rapid, irreversible damage.

  • Binding of isohemagglutinins to allograft endothelial cells activates the classical complement cascade, triggering rapid microvascular thrombosis, diffuse endothelial denudation, and hyperacute rejection (HAR) within minutes to hours following surgical vascular reperfusion.

• Standard ABO Matching Paradigm:

  • Standard red cell transfusion guidelines dictate organ allocation compatibility:

  • Blood Group O serves as the universal donor.

  • Blood Group AB serves as the universal recipient.

• ABO-Incompatible (ABOi) Transplantation Protocols:

  • Implemented primarily in living-donor kidney and liver transplantation programs.

  • Pre-transplant Desensitization:

  • Pre-transplant plasmapheresis (plasma exchange) or antigen-specific immunoadsorption aimed at lowering anti-A or anti-B isohemagglutinin titers to safe levels ($\le 1:8$ or $1:16$).

  • Targeted B-cell depletion using the anti-CD20 chimeric monoclonal antibody Rituximab.

  • Administration of Intravenous Immunoglobulin (IVIg) for immunomodulation and pathogen protection.

  • Accommodation Phenomenon:

  • A state wherein the transplanted organ maintains normal vascular architecture and function and resists humoral rejection despite the subsequent, gradual reappearance of circulating anti-ABO isohemagglutinins in recipient serum.

HLA Allele Nomenclature and High-Resolution Typing Methodologies

• Standardized WHO HLA Nomenclature:

  • HLA alleles are documented using standardized, colon-delimited nomenclature (e.g., $\text{HLA-A}*02:01:01:02L$):

  • $\text{HLA-A}$: Indicates the specific gene locus.

  • *: Molecular typing separator denoting DNA-based typing.

  • $02$ (Field 1): Allele family, historically corresponding to the serological antigen designation (e.g., HLA-A2).

  • $01$ (Field 2): Specific protein sequence variation (subtype conferring amino acid changes in the polypeptide chain).

  • $01$ (Field 3): Synonymous (silent) nucleotide substitution within the protein-coding exons.

  • $02$ (Field 4): Nucleotide sequence variation within non-coding regions (introns, $5'$ UTR, or $3'$ UTR).

  • $L$ (Expression Suffix): Suffix denoting altered phenotypic expression levels:

    • $L$: Low cell-surface expression.

    • $N$: Null allele (no protein product expressed).

    • $S$: Protein produced exclusively as a secreted molecule.

• Comparative HLA Typing Methodologies:

  • Serological (Microlymphocytotoxicity):

  • Principle: Antibody-mediated complement-dependent lysis of living donor/recipient peripheral blood lymphocytes.

  • Resolution: Low resolution (antigen-level specificity, e.g., HLA-A2).

  • Turnaround Time: $3\text{--}5\,\text{hours}$.

  • Primary Clinical Application: Historical baseline technique; largely superseded by contemporary DNA-based molecular testing.

  • PCR-SSP (Sequence-Specific Primers):

  • Principle: PCR amplification using 5' and 3' allele-specific primer pairs followed by agarose gel electrophoresis detection of amplicon presence or absence.

  • Resolution: Intermediate to high resolution.

  • Turnaround Time: $2\text{--}3\,\text{hours}$.

  • Primary Clinical Application: Urgent HLA typing for deceased organ donor allocation; rapid confirmation testing.

  • PCR-SSO (Sequence-Specific Oligonucleotides):

  • Principle: Batch locus amplification via PCR followed by hybridization of denatured amplicons to sequence-specific oligonucleotide probes conjugated to distinct fluorescent microbeads (Luminex suspension array technology).

  • Resolution: Intermediate resolution.

  • Turnaround Time: $4\text{--}6\,\text{hours}$.

  • Primary Clinical Application: Batch screening of waitlist transplant candidates; registration of deceased donor pools.

  • NGS (Next-Generation Sequencing):

  • Principle: Massively parallel, clonal sequencing covering full gene lengths or core polymorphic exons (exons 2 to 4 for HLA Class I; exons 2 to 3 for HLA Class II).

  • Resolution: High resolution (definitive 4-field allele-level typing, e.g., $A*02:01:01:01$), resolving phase ambiguities.

  • Turnaround Time: $24\text{--}72\,\text{hours}$.

  • Primary Clinical Application: Pre-transplant living donor workup; hematopoietic stem cell transplantation (HSCT) donor matching registries.

Assessment of Anti-HLA Sensitization and Solid-Phase Antibody Profiling

• Sensitization Pathways and DSA Significance:

  • Transplant recipients acquire circulating alloantibodies against non-self HLA antigens via prior sensitizing events: blood or platelet transfusions, previous allografts, or pregnancy (exposure to paternal fetal antigens).

  • The persistence of circulating donor-specific anti-HLA antibodies (DSA) introduces high clinical vulnerability to hyperacute rejection (HAR) and acute antibody-mediated rejection (AMR).

• PRA versus Calculated PRA (cPRA):

  • Panel Reactive Antibody (PRA): Historical assay measuring the percentage of cell targets lysed when recipient serum was tested across an unselected panel of donor lymphocytes; confounded by panel composition biases.

  • Calculated Panel Reactive Antibody (cPRA): Contemporary standard calculation. Reflects the exact proportion of donors within the national or regional organ allocation pool who express unacceptable HLA antigens to which the candidate possesses pre-formed antibodies.

  • Clinical Meaning of Elevated cPRA: A cPRA of $99\%$ denotes that $99\%$ of potential deceased donors possess unacceptable HLA antigens incompatible with the candidate, leaving a compatible donor pool of only $1\%$, which necessitates prioritization policies (e.g., UNOS allocation points) or enrollment in kidney paired donation programs.

• Solid-Phase Luminex Single Antigen Bead (SAB) Technology:

  • Gold-standard assay platform for identifying and semiquantitatively profiling circulating anti-HLA antibodies.

  • Step-by-Step Procedure:

  • Polystyrene microspheres, each covalently coated with a single recombinant, cloned human HLA Class I or Class II allele, are incubated with diluted recipient serum.

  • Non-adherent, unbound serum immunoglobulins are eliminated through washing cycles.

  • Phycoerythrin (PE)-conjugated goat anti-human $IgG$ secondary antibody is added to bind bead-tethered anti-HLA antibodies.

  • Dual-laser flow analyzer records the Mean Fluorescence Intensity (MFI) for each uniquely color-coded bead, quantifying antibody strength.

• Analytical Caveats of Single Antigen Bead Testing:

  • Prozone Phenomenon:

  • Occurs in serum with high-titer, complement-fixing anti-HLA antibodies.

  • Endogenous complement component $C1$ binds the Fc region of the bead-bound anti-HLA antibodies, sterically blocking secondary anti-human $IgG$ reporter antibodies from binding, yielding an artifactually low or negative MFI.

  • Mitigation Strategies: Heat inactivation of recipient serum (to denature complement), addition of EDTA (to chelate divalent cations and disassemble the $C1$ complex), or serial dilution of serum.

  • Denatured HLA Antigens:

  • Manufacturing processes or bead storage can cause partial denaturation of recombinant HLA proteins on the microsphere.

  • Denaturation exposes non-physiological, cryptic epitopes, causing false-positive in vitro reactivity that lacks clinical or in vivo relevance.

Donor-Recipient Crossmatching Methodologies

• Crossmatch Fundamentals:

  • Crossmatching assesses direct compatibility by evaluating whether the recipient serum harbors antibodies targeting lymphocytes obtained from a specific potential donor.

• Complement-Dependent Cytotoxicity Crossmatch (CDC-XM):

  • Developed by Paul Terasaki; serves as the foundational test for allograft histocompatibility.

  • Mechanism:

  • Isolated donor T lymphocytes (expressing Class I) or B lymphocytes (expressing Class I and Class II) are incubated with recipient serum.

  • Exogenous rabbit complement is added to the mixture.

  • If complement-binding anti-HLA antibodies are bound to donor cell membranes, the classical complement cascade is activated, assembling the membrane attack complex (MAC; $C5b\text{-}9$) to induce cell lysis.

  • Lysis is quantified microscopically using dye-exclusion reagents (eosin Y, trypan blue, or fluorescence viability dyes such as ethidium bromide and acridine orange).

  • Antihuman Globulin (AHG) Augmentation:

  • Addition of antihuman globulin (AHG-CDC) bridges adjacent recipient $IgG$ antibodies on the target cell surface, maximizing $C1q$ binding and markedly amplifying cytotoxicity detection sensitivity.

  • Dithiothreitol (DTT) Reduction:

  • DTT chemically cleaves the interchain disulfide bridges of pentameric $IgM$ without altering monomeric $IgG$.

  • If a positive crossmatch converts to negative following DTT treatment, the reactivity is driven by clinically benign auto-$IgM$ or non-complement-fixing anti-HLA $IgM$, confirming the absence of destructive donor-specific $IgG$.

• Flow Cytometric Crossmatch (FCXM):

  • Demonstrates $10\text{ to }100\text{ times}$ greater analytical sensitivity than CDC-XM.

  • Methodology:

  • Recipient serum is incubated with isolated donor peripheral blood mononuclear cells or nodal lymphocytes.

  • Cells are washed and stained with a 3-color fluorochrome-conjugated monoclonal antibody cocktail:

    • Anti-CD3: Identifies donor T lymphocytes.

    • Anti-CD19 or Anti-CD20: Identifies donor B lymphocytes.

    • $F(ab')_2$ fragment anti-human $IgG$: Detects bound recipient alloantibodies without non-specific Fc-receptor interaction.

  • Readout:

  • Flow cytometry quantifies the Mean Channel Shift (MCS) relative to an autologous or negative control serum.

  • Interpretation:

  • Positive T-cell FCXM indicates low-titer anti-HLA Class I DSA.

  • Positive B-cell FCXM indicates anti-HLA Class II DSA or low-titer Class I DSA.

• Virtual Crossmatch (vXM):

  • An electronic risk-assessment process comparing the patient's characterized antibody profile (determined by high-resolution Luminex SAB) against the donor's molecular HLA genotype.

  • If the prospective donor possesses none of the recipient's unacceptable HLA antigens, the physical crossmatch is predicted to be negative.

  • Allows organ allocation to proceed without delaying organ procurement for physical crossmatching, substantially reducing cold ischemia times in sensitized recipients.

Pre-Transplant Histocompatibility Algorithm and Clinical Risk Stratification

• Comprehensive Pre-Transplant Testing Algorithm:

  • The complete diagnostic workflow from candidate evaluation to immunological risk stratification proceeds through five core operational stages:

• Step 1: ABO Blood Group Compatibility:

  • Determine ABO identity. If ABO compatible, advance directly to HLA typing. If incompatible, evaluate eligibility for ABO-incompatible desensitization protocols or paired kidney exchange.

• Step 2: High-Resolution HLA Genotyping:

  • Perform molecular HLA typing (NGS, PCR-SSO, or PCR-SSP) covering:

    • Class I loci: HLA-A, HLA-B, HLA-C.

    • Class II loci: HLA-DRB1, HLA-DRB3/4/5, HLA-DQA1, HLA-DQB1, HLA-DPA1, HLA-DPB1.

• Step 3: Recipient Antibody Profiling:

  • Screen recipient serum via Luminex Single Antigen Bead (SAB) assays; determine cPRA and explicitly catalog all donor-specific antibodies (DSA).

• Step 4: Virtual Crossmatching (vXM):

  • Cross-reference the identified anti-HLA antibody repertoire against the donor's defined HLA alleles.

• Step 5: Physical Crossmatching and Risk Assignment:

  • Complete physical crossmatching via CDC-XM and FCXM to define final clinical stratification.

  • Clinical Stratification and Crossmatch Result Matrix:

• T-cell CDC (+) / FCXM (+):

  • Luminex SAB Finding: High MFI DSA directed against HLA Class I.

  • Clinical Interpretation: High-titer cytotoxic anti-Class I DSA present.

  • Recommended Action: Absolute contraindication to transplantation; hyperacute rejection is inevitable in the absence of intensive rescue protocols.

• T-cell CDC (-) / FCXM (+):

  • Luminex SAB Finding: Low-to-moderate MFI DSA.

  • Clinical Interpretation: Low-titer or non-complement-fixing anti-Class I DSA.

  • Recommended Action: Proceed with extreme caution; mandates lymphocyte-depleting induction therapy (e.g., antithymocyte globulin [Thymoglobulin]) with or without perioperative plasmapheresis.

• Isolated B-cell CDC (+):

  • Luminex SAB Finding: High MFI DSA directed against HLA Class II, or non-HLA auto-$IgM$.

  • Clinical Interpretation: Anti-Class II DSA or clinically benign auto-$IgM$.

  • Recommended Action: Perform DTT reduction assay; if B-cell reactivity persists due to bona fide anti-HLA Class II $IgG$ DSA, the recipient faces an elevated risk of early acute antibody-mediated rejection (AMR).

• T (-) / B (-) CDC and FCXM:

  • Luminex SAB Finding: No detectable DSA.

  • Clinical Interpretation: Immunologically negative crossmatch.

  • Recommended Action: Proceed to transplantation using standard induction and baseline maintenance immunosuppressive therapy.

Emerging Diagnostic Modalities and Reference Literature

• Advanced Immunodiagnostics in Histocompatibility:

  • C1q and C3d Binding Assays:

  • Specialized modifications of the solid-phase Luminex SAB platform.

  • Functionally discriminate complement-fixing anti-HLA antibody subclasses ($IgG1$ and $IgG3$) from non-complement-binding subclasses ($IgG2$ and $IgG4$).

  • Provides superior predictive accuracy for identifying clinically destructive DSAs that drive graft pathology.

  • Endothelial Cell Crossmatch and Non-HLA Antibodies:

  • Diagnostic assessment targeting non-classical allogeneic and autoimmune endothelial surface targets in allograft recipients suffering allograft rejection in the absence of anti-HLA DSAs.

  • Targets include Angiotensin II Type 1 Receptor ($AT_1R$), Endothelin-1 Type A Receptor ($ET_AR$), and Major Histocompatibility Complex Class I-Related Chain A (MICA).

  • Donor-Derived Cell-Free DNA (dd-cfDNA):

  • Non-invasive post-transplant biomarker for monitoring graft integrity.

  • Microvascular damage and cellular apoptosis within the allograft release fragmented donor genomic DNA into the recipient bloodstream.

  • Plasma dd-cfDNA levels exceeding $>0.5\text{--}1.0\%$ strongly correlate with ongoing active antibody-mediated rejection or acute cellular rejection, preceding serum creatinine elevations.

• Foundational References and Standards:

  • Terasaki, P. I., & McClelland, J. D. (1964). Microdroplet assay of human serum cytotoxins. Nature, 204(4962), 998–1000.

  • Bray, R. A., Gebel, H. M., & Townsend, R. (2004). The flow cytometric crossmatch: dual-color versus three-color analysis. Transplantation Proceedings, 36(3), 740–743.

  • Zachary, A. A., & Leffell, M. S. (2016). HLA antibodies: Detection, characterization, and clinical relevance. Immunohematology, 32(3), 101–110.

  • Loupy, A., & Lefaucheur, C. (2018). Antibody-mediated rejection of solid-organ allografts. New England Journal of Medicine, 379(12), 1150–1160.

  • American Society for Histocompatibility and Immunogenetics (ASHI). Standards for Accredited Laboratories: Histocompatibility and Immunogenetics Testing.